For patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy, treatment with pazopanib (a drug that targets the growth of new cancer-related blood vessels) nearly tripled progression-free ...
May 15, 2012
0
0
The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. ...
Apr 1, 2012
0
0
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
Feb 6, 2012
0
0
The E2810 research study was conducted to determine whether taking the oral drug pazopanib (Votrient) following surgery to remove further metastases in patients with advanced renal cell carcinoma would improve their disease-free ...
Jun 3, 2019
0
2
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Oct 1, 2012
0
0
